Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 249

1.

Quantification of HIV-1 p24 by a highly improved ELISA: an alternative to HIV-1 RNA based treatment monitoring in patients from Abidjan, Côte d'Ivoire.

Tehe A, Maurice C, Hanson DL, Borget MY, Abiola N, Maran M, Yavo D, Tomasik Z, Böni J, Schüpbach J, Nkengasong JN.

J Clin Virol. 2006 Nov;37(3):199-205. Epub 2006 Sep 14.

PMID:
16973409
2.

Field evaluation of an improved assay using a heat-dissociated p24 antigen for adults mainly infected with HIV-1 CRF02_AG strains in Côte d'Ivoire, West Africa.

Bonard D, Rouet F, Toni TA, Minga A, Huet C, Ekouévi DK, Dabis F, Salamon R, Rouzioux C; ANRS 1220 PRIMO-CI Study Group.

J Acquir Immune Defic Syndr. 2003 Nov 1;34(3):267-73.

PMID:
14600570
4.

Simple monitoring of antiretroviral therapy with a signal-amplification-boosted HIV-1 p24 antigen assay with heat-denatured plasma.

Böni J, Opravil M, Tomasik Z, Rothen M, Bisset L, Grob PJ, Lüthy R, Schüpbach J.

AIDS. 1997 May;11(6):F47-52.

PMID:
9143600
5.

Antiretroviral treatment monitoring with an improved HIV-1 p24 antigen test: an inexpensive alternative to tests for viral RNA.

Schüpbach J, Böni J, Flepp M, Tomasik Z, Joller H, Opravil M.

J Med Virol. 2001 Oct;65(2):225-32.

PMID:
11536227
6.

Evaluation of p24-based antiretroviral treatment monitoring in pediatric HIV-1 infection: prediction of the CD4+ T-cell changes between consecutive visits.

Brinkhof MW, Böni J, Steiner F, Tomasik Z, Nadal D, Schüpbach J.

J Acquir Immune Defic Syndr. 2006 Apr 15;41(5):557-62.

PMID:
16652029
7.

Medium-term survival, morbidity and immunovirological evolution in HIV-infected adults receiving antiretroviral therapy, Abidjan, Côte d'Ivoire.

Seyler C, Anglaret X, Dakoury-Dogbo N, Messou E, Touré S, Danel C, Diakité N, Daudié A, Inwoley A, Maurice C, Tonwe-Gold B, Rouet F, N'Dri-Yoman T, Salamon R; ANRS 1203 Study Group.

Antivir Ther. 2003 Oct;8(5):385-93.

PMID:
14640385
8.

Plasma virion reverse transcriptase activity and heat dissociation-boosted p24 assay for HIV load in Burkina Faso, West Africa.

Lombart JP, Vray M, Kafando A, Lemée V, Ouédraogo-Traoré R, Corrigan GE, Plantier JC, Simon F, Braun J.

AIDS. 2005 Aug 12;19(12):1273-7.

PMID:
16052082
9.
10.

Evaluation of HIV-1 p24 antigenemia and level of CD8+CD38+ T cells as surrogate markers of HIV-1 RNA viral load in HIV-1-infected patients in Dakar, Senegal.

Ondoa P, Dieye TN, Vereecken C, Camara M, Diallo AA, Fransen K, Litzroth A, Mboup S, Kestens L.

J Acquir Immune Defic Syndr. 2006 Apr 1;41(4):416-24.

PMID:
16652048
11.

Optimized virus disruption improves detection of HIV-1 p24 in particles and uncovers a p24 reactivity in patients with undetectable HIV-1 RNA under long-term HAART.

Schüpbach J, Tomasik Z, Knuchel M, Opravil M, Günthard HF, Nadal D, Böni J; Swiss HIV Cohort Study; Swiss HIV Mother + Child Cohort Study.

J Med Virol. 2006 Aug;78(8):1003-10.

PMID:
16789014
12.
13.

Pediatric viral human immunodeficiency virus type 1 RNA levels, timing of infection, and disease progression in African HIV-1-infected children.

Rouet F, Sakarovitch C, Msellati P, Elenga N, Montcho C, Viho I, Blanche S, Rouzioux C, Dabis F, Leroy V; Abidjan ANRS 049 Ditrame Study Group.

Pediatrics. 2003 Oct;112(4):e289.

PMID:
14523214
14.

Maternal 12-month response to antiretroviral therapy following prevention of mother-to-child transmission of HIV type 1, Ivory Coast, 2003-2006.

Coffie PA, Ekouevi DK, Chaix ML, Tonwe-Gold B, Clarisse AB, Becquet R, Viho I, N'dri-Yoman T, Leroy V, Abrams EJ, Rouzioux C, Dabis F.

Clin Infect Dis. 2008 Feb 15;46(4):611-21. doi: 10.1086/526780.

PMID:
18197758
15.

Performance of drug-resistance genotypic assays among HIV-1 infected patients with predominantly CRF02_AG strains of HIV-1 in Abidjan, Cote d'Ivoire.

Bilé EC, Adjé-Touré C, Borget MY, Kalou M, Diomande F, Chorba T, Nkengasong JN.

J Clin Virol. 2005 Jan;32(1):60-6.

PMID:
15572008
16.

Measurement of HIV-1 CRF02_AG-specific T cell responses indicates the dominance of a p24gag epitope in blood donors in Abidjan, Cote d'Ivoire.

Chahroudi A, Sawadogo S, Ellenberger D, Pieniazek D, Borget-Alloue MY, Aidoo M, Koblavi-Deme S, Fernandez-Vina M, Maurice C, Chorba T, Nkengasong JN, McNicholl JM.

J Infect Dis. 2005 Oct 15;192(8):1417-21. Epub 2005 Sep 9.

PMID:
16170760
17.

HIV-1 p24 may persist during long-term highly active antiretroviral therapy, increases little during short treatment breaks, and its rebound after treatment stop correlates with CD4(+) T cell loss.

Schüpbach J, Günthard H, Joos B, Fischer M, Böni J, Tomasik Z, Yerly S, Perrin L, Battegay M, Furrer H, Vernazza P, Bernasconi E, Hirschel B; Swiss HIV Cohort Study.

J Acquir Immune Defic Syndr. 2005 Nov 1;40(3):250-6.

PMID:
16249697
18.

Clinical and biological evolution of HIV-1 seroconverters in Abidjan, Côte d'Ivoire, 1997-2000.

Salamon R, Marimoutou C, Ekra D, Minga A, Nerrienet E, Huët C, Gourvellec G, Bonard D, Coulibaly I, Combe P, Dabis F, Bondurand A, Montagnier L.

J Acquir Immune Defic Syndr. 2002 Feb 1;29(2):149-57.

PMID:
11832684
19.

Virologic and immunologic responses to antiretroviral therapy among HIV-1 and HIV-2 dually infected patients: case reports from Abidjan, Côte d'Ivoire.

Borget MY, Diallo K, Adje-Toure C, Chorba T, Nkengasong JN.

J Clin Virol. 2009 May;45(1):72-5. doi: 10.1016/j.jcv.2009.03.011. Epub 2009 Apr 17.

PMID:
19375979
20.

Changes in HIV RNA viral load, CD4+ T-cell counts, and levels of immune activation markers associated with anti-tuberculosis therapy and cotrimoxazole prophylaxis among HIV-infected tuberculosis patients in Abidjan, Cote d'Ivoire.

Kalou M, Sassan-Morokro M, Abouya L, Bile C, Maurice C, Maran M, Tossou O, Roels T, Greenberg AE, Wiktor SZ, Nkengasong JN.

J Med Virol. 2005 Feb;75(2):202-8.

PMID:
15602734

Supplemental Content

Support Center